Leerink Partners Has Lowered Expectations for Ardent Health (NYSE:ARDT) Stock Price

Ardent Health (NYSE:ARDT) had its target price cut by equities researchers at Leerink Partners from $16.00 to $15.00 in a report issued on Friday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Leerink Partners’ price objective points to a potential upside of 66.85% from the company’s current price.

A number of other equities analysts have also recently weighed in on ARDT. Morgan Stanley reissued an “equal weight” rating and issued a $12.00 price objective (down from $22.00) on shares of Ardent Health in a research report on Friday, November 14th. Royal Bank Of Canada reduced their price target on Ardent Health from $21.00 to $16.00 and set an “outperform” rating for the company in a report on Friday, November 14th. KeyCorp lowered Ardent Health from an “overweight” rating to a “sector weight” rating in a research note on Monday, November 17th. Guggenheim cut their target price on Ardent Health from $18.00 to $15.00 and set a “buy” rating on the stock in a research report on Tuesday, November 18th. Finally, Truist Financial reduced their target price on Ardent Health from $21.00 to $13.00 and set a “buy” rating for the company in a research note on Friday, November 14th. Seven investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $14.50.

Ardent Health Stock Down 4.8%

NYSE ARDT traded down $0.45 on Friday, reaching $8.99. The company had a trading volume of 110,316 shares, compared to its average volume of 405,836. The company has a debt-to-equity ratio of 0.67, a current ratio of 2.08 and a quick ratio of 1.95. Ardent Health has a 1 year low of $8.07 and a 1 year high of $15.48. The firm has a 50-day moving average of $9.01 and a 200-day moving average of $11.03. The firm has a market capitalization of $1.29 billion, a PE ratio of 9.36, a P/E/G ratio of 5.31 and a beta of 0.46.

Ardent Health (NYSE:ARDT) last posted its earnings results on Wednesday, March 4th. The company reported $0.32 EPS for the quarter, missing analysts’ consensus estimates of $0.35 by ($0.03). The firm had revenue of $1.61 billion for the quarter, compared to analyst estimates of $1.63 billion. Ardent Health had a return on equity of 14.46% and a net margin of 2.15%.Ardent Health has set its FY 2026 guidance at 0.900-1.270 EPS. On average, equities research analysts anticipate that Ardent Health will post 1.23 EPS for the current fiscal year.

Hedge Funds Weigh In On Ardent Health

Hedge funds have recently added to or reduced their stakes in the business. CWM LLC raised its holdings in shares of Ardent Health by 990.6% during the second quarter. CWM LLC now owns 2,203 shares of the company’s stock worth $30,000 after purchasing an additional 2,001 shares during the period. Caitong International Asset Management Co. Ltd grew its position in shares of Ardent Health by 1,177.7% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,862 shares of the company’s stock valued at $25,000 after buying an additional 2,638 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Ardent Health during the 3rd quarter valued at about $61,000. KLP Kapitalforvaltning AS acquired a new stake in Ardent Health during the third quarter worth about $80,000. Finally, New York State Common Retirement Fund lifted its holdings in Ardent Health by 121.4% in the second quarter. New York State Common Retirement Fund now owns 6,200 shares of the company’s stock worth $85,000 after acquiring an additional 3,400 shares during the last quarter.

Key Stories Impacting Ardent Health

Here are the key news stories impacting Ardent Health this week:

• Positive Sentiment: Company announced an operational “impact” program and expansion of AI-driven care that it says could drive $485M–$535M of EBITDA in 2026 — a potential long‑term earnings lever if realized. Ardent outlines $485M-$535M 2026 EBITDA target
• Neutral Sentiment: Management held its Q4 earnings call and posted related slides/transcript — useful for investors wanting management commentary on collectability, reserve methodology and the impact program. Review the transcript and slide deck for details on assumptions. Q4 2025 earnings call transcript
• Negative Sentiment: Q4 results missed estimates — $0.32 EPS vs. $0.35 consensus and revenue $1.61B vs. $1.63B — and management cut FY‑2026 EPS guidance to $0.90–$1.27 versus a ~$1.40 consensus, creating near‑term earnings disappointment. Earnings, guidance and press materials
• Negative Sentiment: Multiple law firms have filed or solicited plaintiffs in a securities class action tied to a Nov. 2025 disclosure about receivable reserving (an alleged “180‑day cliff”) and an asserted $97M accounting shock — increasing legal overhang and investor uncertainty. Note a March 9 deadline for lead‑plaintiff applications. Hagens Berman investor alert on alleged accounting issues
• Negative Sentiment: Follow‑on notices from several national firms (Rosen, Robbins Geller, Pomerantz, BFA, others) amplify the litigation narrative and may pressure the stock while uncertainty persists. RGRD Law class action notice

About Ardent Health

Ardent Health, listed on the New York Stock Exchange under the ticker ARDT, is a healthcare delivery company focused on acquiring, developing and managing acute care hospitals and complementary outpatient facilities across the United States. The company’s integrated platform encompasses both inpatient and outpatient services, designed to provide end-to-end care solutions and address the full continuum of patient needs.

Through its network, Ardent Health operates general hospitals, emergency departments, ambulatory surgery centers, urgent care clinics, rehabilitation and post-acute care facilities.